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ABSTRACT Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the
pncA gene inMycobacterium tuberculosis. Molecular identification of mutations in pncA offers the potential for rapid detection
of pyrazinamide resistance (PZAr). However, the genetic variants are highly variable and scattered over the full length of pncA,
complicating the development of a molecular test. We performed a large multicenter study assessing pncA sequence variations in
1,950 clinical isolates, including 1,142 multidrug-resistant (MDR) strains and 483 fully susceptible strains. The results of pncA
sequencing were correlated with phenotype, enzymatic activity, and structural and phylogenetic data. We identified 280 genetic
variants which were divided into four classes: (i) very high confidence resistance mutations that were found only in PZAr strains
(85%), (ii) high-confidence resistance mutations found in more than 70% of PZAr strains, (iii) mutations with an unclear role
found in less than 70% of PZAr strains, and (iv) mutations not associated with phenotypic resistance (10%). Any future molecu-
lar diagnostic assay should be able to target and identify at least the very high and high-confidence genetic variant markers of
PZAr; the diagnostic accuracy of such an assay would be in the range of 89.5 to 98.8%.
IMPORTANCE Conventional phenotypic testing for pyrazinamide resistance inMycobacterium tuberculosis is technically chal-
lenging and often unreliable. The development of a molecular assay for detecting pyrazinamide resistance would be a break-
through, directly overcoming both the limitations of conventional testing and its related biosafety issues. Although the main
mechanism of pyrazinamide resistance involves mutations inactivating the pncA enzyme, the highly diverse genetic variants
scattered over the full length of the pncA gene and the lack of a reliable phenotypic gold standard hamper the development of
molecular diagnostic assays. By analyzing a large number of strains collected worldwide, we have classified the different genetic
variants based on their predictive value for resistance which should lead to more rapid diagnostic tests. This would assist clini-
cians in improving treatment regimens for patients.
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Pyrazinamide (PZA) is a key drug in current and future tuber-culosis (TB) treatment regimens. It has a high sterilizing ca-
pacity in vivo, but it is not active against Mycobacterium tubercu-
losis complex (MTBC) strains growing at neutral pH (1–4).
In addition to its crucial role in the standard short-course reg-
imen for TB treatment, PZA is used in the treatment of patients
infected with strains that are multidrug resistant (MDR) (resistant
to at least isoniazid and rifampin). Here PZA has a strong impact
on the success rates of MDR treatment and may allow a shortening
of current MDR therapy (5). Finally, PZA is the only first-line
drug that will be maintained in all regimens in the near future (6).
These new regimens aim at reducing the treatment duration of
susceptible, drug-resistant (especially MDR TB and extensively
resistant) strain variants.
The essential role of PZA underlines the need for accurate and
rapid detection of PZA resistance that is very difficult with current
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phenotypic tests (7). The difficulties with culture-based PZA sus-
ceptibility testing result from several factors, including subopti-
mal test media with unreliable pH and larger inocula that reduce
the activity of PZA (8, 9). Furthermore, the critical concentration
itself may result in inconsistent results for isolates with a PZA MIC
close to this concentration (10). While for isoniazid and rifampin,
highly reliable culture-based drug susceptibility testing (DST)
techniques and rapid molecular assays such as the line probe assay
MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) and
the cartridge-based Xpert MTB/RIF assay (Cepheid, Sunnyvale,
CA) are available (11), no commercial molecular assays are cur-
rently marketed for PZA.
Great efforts have been made in understanding molecular re-
sistance mechanisms. PZA is a prodrug that needs to be converted
to an active compound, pyrazinoic acid, by the bacterial pyrazi-
namidase (PZase) (encoded by pncA). Mutations/variations in
pncA leading to the loss of PZase activity are the major mechanism
leading to PZA resistance (PZAr) (4, 12). However, while high
numbers of PZAr cases can be related to inactivation of the PZase,
the genetic variants, including single nucleotide polymorphisms
(SNPs) and small deletions, are highly diverse and scattered over
the full length of the 561 bp of the pncA gene (4, 12). This compli-
cates the development of molecular tests, as no “hot spot region”
comprising the majority of mutations is present in the pncA gene,
as is present in rpoB for rifampin resistance.
Accordingly, future molecular approaches to detect PZAr in
clinical isolates need to cover at least a significant number of pos-
sible variants, if not the complete gene, to reach a high sensitivity
(e.g., using approaches based on classical Sanger sequencing or
next-generation genome sequencing). These techniques must be
combined with an appropriate interpretation algorithm/database
that distinguishes SNPs clearly associated with drug resistance
from those for which the impact for developing PZAr is unclear,
e.g., due to phylogenic variants found in members of the MTBC
(13, 14). In-depth knowledge of the variants found in PZAr strains
combined with evidence-based correlation with resistance pheno-
types are needed to develop large-scale databases ensuring valid
data interpretation. The fact that such a valid data basis is cur-
rently lacking represents a substantial limitation for molecular
PZA DST.
To tackle this question, we performed a large multicenter study
assessing pncA sequence variations in 1,950 MTBC pan-
susceptible strains and PZAr strains. The strains were classified in
phylogenetic lineages to identify variants that are phylogenetically
informative but not likely to be involved in PZAr and those that
are occurring in strains from different groups and are obviously
under positive selection. Using this comprehensive approach, we
could catalog 239 high-confidence PZAr mutations and a number
of pncA variants most likely not involved in PZAr.
RESULTS
We studied 1,950 clinical isolates, including 1,142 MDR strains
and 483 fully susceptible strains (see Table S1 in the supplemental
material). By phenotypic DST, 1,107 clinical isolates were suscep-
tible to PZA, whereas 843 were classified as PZAr. Genotyping data
were available for 1,853 isolates (95.0%). Predominant lineages
among the strains investigated were Beijing (47.8%), LAM
(9.0%), Ural (7.7%), and Haarlem (5.0%). Other lineages found
(Ghana, EAI, Delhi/CAS, H37Rv_like, Uganda I and II, West Af-
rican 1 and 2, S, Cameroon, Sierra Leone 1 and 2, Mycobacte-
rium bovis, H37Rv, UZB_H37Rv_like, New-1, X, CAS, TUR,and
Mycobacteriummicroti vole) each represented less than 5% of iso-
lates (Fig. 1). Six percent were classified as EuroAmerican strains
not belonging to a valid lineage described previously (“other un-
defined,” as described in reference 15), and 5.2% of strains were
classified as “unknown,” because it was not possible to assign a
defined lineage.
Considering the sequencing results, 1,062 (54.5%) isolates
were found to be wild type (WT) for the pncA gene, whereas 888
harbored variations in the pncA gene that amounted to a total of
280 genetic variants comprising 67 insertions or deletions (indels)
and 213 SNPs (see Table S2 in the supplemental material). The
PZase enzymatic activity was available for 251 clinical isolates ac-
counting for 90 different genetic variants. Considering the distri-
bution of the mutations across the entire gene, 73 (39.0%) codons
were not affected by mutations, whereas the remaining 114
codons presented one or more mutations (Fig. 2). Only 50 codons
showed a frequency of mutation over the mean value of 0.5%, but
despite this, a clear hot spot region could not be found; the most
FIG 1 Pie chart reporting percentages of lineages for isolates included in the
study.
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frequently affected regions (representing more than 70% of mu-
tated strains) were found at the promoter (positions13 to3)
and at codons 6 to 15, 50 to 70, 90 to 100, 130 to 145, and 170 to
175 (Fig. 3).
For mutations found in both PZA-sensitive (PZAs) and PZAr
isolates, enzymatic activity and structural analysis results were
used to adjust for possible errors in phenotypic DST whenever
possible and to obtain a “revised DST” (included as “DST rev” in
Table S1 in the supplemental material). Accordingly, 56 clinical
isolates originally reported as PZAs were reclassified as PZAr (Ta-
ble S1). The final distribution of mutations among revised PZAs
and PZAr isolates is summarized in Table 1. To further validate the
classification data, we analyzed the homoplastic occurrence of
particular mutations (e.g., the emergence in strains of two phylo-
genetic lineages [16]). As the homoplasy level is rather low in
MTBC genomes, this confirms that these mutations are most
likely under positive selection and involved in the development of
PZAr.
FIG 2 Number of different mutations found at each codon. Note that multiple mutations and IS6110 are not included. The broken line indicates mean
value.
FIG 3 Frequency of mutations found at each codon (calculated with 888 mutated isolates). Note that multiple mutations and IS6110 are not included. The
dotted line indicates mean value.
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Using this procedure, four classes of genetic variants were
identified: (i) very high confidence resistance mutations that were
found only in PZAr strains (category A), (ii) high-confidence re-
sistance mutations found in more than 70% of PZAr strains (cat-
egory E), (iii) mutations with an unclear role found in less than 70%
in PZAr strains (category D), and (iv) genetic variants (including the
wild type) not involved in phenotypic resistance (category B). Ta-
ble S2 in the supplemental material summarizes these clinically
relevant categories; a graphical overview is provided in Fig. 4.
Mutations conferring PZAr at very high confidence. Out of
the 280 sequence variants identified in pncA, 239 (85.4%) muta-
tions found in 644 clinical isol ates (644/1,950 [33.0%]) were clas-
sified as very high confidence variants associated with phenotypic
PZAr (category A) (see Table S2 in the supplemental material).
Several mutations affect the catalytic residues and amino acids
recruited in the scaffold of the active site or directly/indirectly
involved in the coordination of the Fe2 ion (Asp8Gly/Ala/Glu/
Asn, His51Gln/Tyr, His71Arg, Asp49Glu/Asn/Ala, His57Arg/Tyr/
Gln/Pro, Trp68Arg/Gly/Cys/Stop/Leu, Gln10Pro/Arg, and
His137Pro/Arg/Asp) or residues engaged in the hydrophobic core
(Ile6Thr, Val44Gly, Val139Gly/Leu, Met175Thr/Val, and
Phe94Cys/Ser/Leu). Out of the 90 variants tested, 87 variants, in-
cluding nucleotide substitutions at position11, were also asso-
ciated with negative PZase activity, and 55 genetic variants
(detected in 332 isolates) were found in strains of at least 2 differ-
ent lineages, indicating homoplasy (data not shown). Table 2
reports the mutations mapping in the most frequently affected
regions.
TABLE 1 Distribution of mutations among PZAs and PZAr clinical
isolates
pncA gene No. of isolates (%)
PZAs (n 1,051) PZAr (n 899)
WT 893a (85.0) 158 (15.0)
Mutant 200 (22.2) 699 (77.8)
a Includes 19 isolates harboring silent mutations or mutations at the distal region of the
promoter (100 nucleotides upstream of the start codon).
FIG 4 Distribution of genetic variants across the four categories identified: (i) very high confidence resistance mutations, (ii) high-confidence resistance
mutations, (iii) mutations with an unclear role, and (iv) mutations not involved in phenotypic resistance. The number of isolates belonging to each category is
also reported. The inner ring shows the percentages of mutations affecting the structure of the enzyme for each category of genetic variants. PZA-R, PZA
resistance. *, including wild-type isolates for the pncA gene.
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TABLE 2 Mutations for PZAr affecting the most frequently affected regions of pncA gene and representing more than 70% of mutated cases
Nucleotide changea Result of the mutationb p.Sc p.Rd No. of cases
A-11C Promoter11 0.01497006 0.98502994 5
A-11G Promoter11 0.01497006 0.98502994 35
A-11T Promoter11 0.01497006 0.98502994 1
T-7C Promoter7 0.01497006 0.98502994 4
T-7G Promoter7 0.01497006 0.98502994 1
Del-5¡ G Promoter (del) 0.01497006 0.98502994 2
ATC6ACC Ile6Thr 0.01497006 0.98502994 3
Del14¡ TCATCG FSC 6 (del) 0.01497006 0.98502994 1
GTC7GGC Val7Gly 0.01497006 0.98502994 9
GTC7TTC Val7Phe 0.01497006 0.98502994 2
WT GTC7GGC WT Val7Gly 0.01497006 0.98502994 1
GAC8AAC Asp8Asn 0.01497006 0.98502994 3
GAC8GAA Asp8Glu 0.01497006 0.98502994 6
GAC8GCC Asp8Ala 0.01497006 0.98502994 1
GAC8GGC Asp8Gly 0.01497006 0.98502994 9
GTG9GGG Val9Gly 0.01497006 0.98502994 1
CAG10AAG Gln10Lys 0.01497006 0.98502994 2
CAG10CCG Gln10Pro 0.01497006 0.98502994 21
CAG10CGG Gln10Arg 0.01497006 0.98502994 6
GAC12AAC Asp12Asn 0.01497006 0.98502994
GAC12GAG Asp12Glu 0.01497006 0.98502994 2
GAC12GCC Asp12Ala 0.01497006 0.98502994 6
Ins37¡ GACT FSC 13 (ins) 0.01497006 0.98502994 1
TTC13TCC Phe13Ser 0.01497006 0.98502994 2
TTC13TTG Phe13Leu 0.01497006 0.98502994 3
TGC14CGC Cys14Arg 0.01497006 0.98502994 1
TGC14TGA Cys14Stop 0.01497006 0.98502994 2
WT TGC14CGC WT Cys14Arg 0.01497006 0.98502994 1
Ins44¡ C FSC 15 (ins) 0.01497006 0.98502994 1
Del150¡ T FSC 50 (del) 0.01497006 0.98502994 1
CAC51CAA His51Gln 0.01497006 0.98502994 7
CAC51CCC His51Pro 0.01497006 0.98502994 2
CAC51CGC His51Arg 0.01497006 0.98502994 4
CAC51TAC His51Tyr 0.01497006 0.98502994 3
CCG54CAG Pro54Gln 0.01497006 0.98502994 4
CCG54CGG Pro54Arg 0.01497006 0.98502994 1
CCG54CTG Pro54Leu 0.01497006 0.98502994 4
CCG54TCG Pro54Ser 0.01497006 0.98502994 1
CAC57CAG His57Gln 0.01497006 0.98502994 1
CAC57CCC His57Pro 0.01497006 0.98502994 1
CAC57CGC His57Arg 0.01497006 0.98502994 14
CAC57GAC His57Asp 0.01497006 0.98502994 10
CAC57TAC His57Tyr 0.01497006 0.98502994 5
WT CAC57CGC WTHis57Arg 0.01497006 0.98502994 2
TTC58CTC Phe58Leu 0.01497006 0.98502994 7
CCG62CTG Pro62Leu 0.01497006 0.98502994 3
Del186¡ C FSC 62 (del) 0.01497006 0.98502994 3
Ins185¡ 4 nt FSC 62 (ins) 0.01497006 0.98502994 1
Ins186¡ A FSC 62 (ins) 0.01497006 0.98502994 1
GAC63GGC Asp63Gly 0.01497006 0.98502994 4
Ins192¡ A FSC 64 (ins) 0.01497006 0.98502994 1
TAT64TAG Tyr64stop 0.01497006 0.98502994 3
Ins193¡ A FSC 65 (ins) 0.01497006 0.98502994 1
Ins193¡ TATCAGG FSC 65 (ins) 0.01497006 0.98502994 1
TCG67CCG Ser67Pro 0.01497006 0.98502994 2
TGG68CGG Trp68Arg 0.01497006 0.98502994 7
TGG68GGG Trp68Gly 0.01497006 0.98502994 16
TGG68TAG Trp68stop 0.01497006 0.98502994 1
TGG68TGC Trp68Cys 0.01497006 0.98502994 5
TGG68TGT Trp68Cys 0.01497006 0.98502994 1
GAG91TAG Glu91Stop 0.01497006 0.98502994 1
TTC94CTC Phe94Leu 0.01497006 0.98502994 8
TTC94TCC Phe94Ser 0.01497006 0.98502994 3
TTC94TGC Phe94Cys 0.01497006 0.98502994 6
TTC94TTA Phe94Leu 0.01497006 0.98502994 2
(Continued on following page)
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TABLE 2 (Continued)
Nucleotide changea Result of the mutationb p.Sc p.Rd No. of cases
TTC94TTG Phe94Leu 0.01497006 0.98502994 1
WT TTC94CTC WT Phe94Leu 0.01497006 0.98502994 1
TAC95TAG Tyr95stop 0.01497006 0.98502994 1
AAG96AAC Lys96Asn 0.01497006 0.98502994 1
AAG96ACG Lys96Thr 0.01497006 0.98502994 2
AAG96AGG Lys96Arg 0.01497006 0.98502994 1
AAG96CAG Lys96Gln 0.01497006 0.98502994 1
AAG96GAC Lys96Glu 0.01497006 0.98502994 6
Ins288¡ T FSC 96 (ins) 0.01497006 0.98502994 2
Ins288¡ 33 nt FSC 96 (ins) 0.01497006 0.98502994 4
Del291¡ T FSC 97 (del) 0.01497006 0.98502994 1
GGT97AGT Gly97Ser 0.01497006 0.98502994 6
GGT97GAT Gly97Asp 0.01497006 0.98502994 4
GGT97GCT Gly97Ala 0.01497006 0.98502994 1
TAC99TAA Tyr99stop 0.01497006 0.98502994 2
ACC100CCC Thr100Pro 0.01497006 0.98502994 2
ACC100GCC Thr100Ala 0.01497006 0.98502994 1
GTG130GCG Val130Ala 0.01497006 0.98502994 1
GTG130GGG Val130Gly 0.01497006 0.98502994 1
Ins391¡ G FSC 131 (ins) 0.01497006 0.98502994 3
Ins391¡ GG FSC 131 (ins) 0.01497006 0.98502994 2
Ins392¡ G FSC 131 (ins) 0.01497006 0.98502994 2
Ins392¡ GG FSC 131 (ins) 0.01497006 0.98502994 4
Ins393¡ G FSC 131 (ins) 0.01497006 0.98502994 2
Ins393¡ GG FSC 131 (ins) 0.01497006 0.98502994 1
Ins394¡ ATGTGGTCG FSC 131 (ins) 0.01497006 0.98502994 1
TGC131GGTGC FSC 131 (ins) 0.01497006 0.98502994 1
GGT132AGT Gly132Ser 0.01497006 0.98502994 1
GGT132GAT Gly132Asp 0.01497006 0.98502994 1
GGT132GCT Gly132Ala 0.01497006 0.98502994 1
GGT132TGT Gly132Cys 0.01497006 0.98502994 2
ATT133ACT Ile133Thr 0.01497006 0.98502994 17
Del398¡ T FSC 133 (del) 0.01497006 0,98502994 1
GCC134GTC Ala134Val 0.01497006 0.98502994 2
ACC135AAC Thr135Asn 0.01497006 0.98502994 3
ACC135CCC Thr135Pro 0.01497006 0.98502994 4
GAT136TAT Asp136Tyr 0.01497006 0.98502994 3
Ins408¡ A FSC 136 (ins) 0.01497006 0.98502994 4
CAT137CCT His137Pro 0.01497006 0.98502994 1
CAT137CGT His137Arg 0.01497006 0.98502994 1
CAT137GAT His137Asp 0.01497006 0.98502994 1
TGT138CGT Cys138Arg 0.01497006 0.98502994 3
TGT138TGG Cys138Trp 0.01497006 0.98502994 1
Del417¡ G FSC 139 (del) 0.01497006 0.98502994 1
GTG139CTG Val139Leu 0.01497006 0.98502994 3
GTG139GGG Val139Gly 0.01497006 0.98502994 5
CGC140CCC Arg140Pro 0.01497006 0.98502994 1
CAG141CCG Gln141Pro 0.01497006 0.98502994 11
CAG141TAG Gln141stop 0.01497006 0.98502994 1
Ins423¡ CAGACGGCGCCAG FSC 141 (ins) 0.01497006 0.98502994 1
ACG142AAG Thr142Lys 0.01497006 0.98502994 1
ACG142ATG Thr142Met 0.01497006 0.98502994 3
ACG142GCG Thr142Ala 0.01497006 0.98502994 3
GCC143GGC Ala143Gly 0.01497006 0.98502994 1
CTG172CCG Leu172Pro 0.01497006 0.98502994 9
Del514¡ C FSC 172 (del) 0.01497006 0.98502994 1
Ins516¡ CG FSC 172 (ins) 0.01497006 0.98502994 1
ATG175ACG Met175Thr 0.01497006 0.98502994 1
ATG175ATA Met175Ile 0.01497006 0.98502994 10
ATG175GTG Met175Val 0.01497006 0.98502994 6
a A-11C, nucleotide change A to C in position11; Del-5¡ G, deletion of nucleotide G in position5; ATC6AAC, ATC at codon 7 changed to AAC; WT GTC7GGC, double
pattern wild-type GTC at codon 7 changed to GGC; Ins37¡ GACT, GACT inserted at codon 37.
b Promoter11, nucleotidic mutation affecting the promoter region at position11; del, deletion; FSC, frameshift codon; ins, insertion.
c p.S, probability associated with the susceptible phenotype.
d p.R, probability associated with the resistant phenotype.
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Mutations conferring PZAr at high confidence. Nine genetic
variants (32 strains, category E) were found in both PZAr and
PZAs isolates, but with a proportion higher than 70% in PZAr
strains. These mutations were mainly associated with an increase
in free energy and/or structural constraints and were most fre-
quently associated with PZAr (93.5% of cases). We confirmed a
reduced but still present PZase activity for some of these variants
as a development of faint color during the enzymatic assay.
Whereas Leu172Pro was found to be associated with homoplasy,
for other substitutions, the number of cases was too low to con-
sider convergent evolution in different lineages.
Mutations with an unclear role in conferring PZAr. Five ge-
netic variants (21 cases, category D) were found in both PZAr and
PZAs isolates but at a proportion less than 70% in PZAr strains.
Two genetic variants (15 cases) showed borderline behavior in
terms of structure/free energy variation and enzyme activity. Ho-
moplasy was found for the Val139Ala mutation, thus suggesting a
putative role in phenotypic resistance or at least in increasing the
MIC. Pro62Arg, Asp63Ala, and Ser65Pro substitutions (6 cases)
represent another group of mutations belonging to this ambigu-
ous category. Further characterization of these mutations is
needed to better understand their correlation with the PZA phe-
notype.
Mutations not involved in phenotypic resistance. Twenty-
seven genetic variants were not associated with PZAr according to
our classification. Eighteen mutations (163 cases, category C)
were most frequently associated with PZAs (91.4% of cases). It
should be noted that the Val21Ala mutation was also found asso-
ciated with other mutations in category A responsible for PZAr/
PZase negativity. Interestingly, all these mutations were found to
be associated with single lineages; thus, no homoplasy was ob-
served. Further characterization of these mutations is needed to
better understand their role (if any) in PZA susceptibility. The
remaining genetic variants (27 cases, category B) did not affect the
amino acid sequence of the PZase enzyme. We observed two silent
mutations: TCC65TCT (Ser65Ser), GCG38GCC (Ala38Ala). The
Ser65Ser silent mutation was found associated with the Delhi/CAS
lineage. In some cases, sequencing of the upstream region of pncA
allowed the identification of a deletion at position 125 or an
insertion at nucleotide3; however, isolates harboring these ge-
netic variants were found associated with both phenotypic resis-
tance and susceptibility. According to these data, and supported
by the lack of homoplasy for these mutations, the indels detected
do not represent a marker for PZAr.
A total of 1,062 clinical isolates (1,062/1,950 [55.4%]) showed
a WT sequence for the PZase enzyme (included in category B),
and the sequence was associated with PZAs in more than 80% of
cases. Enzymatic assay results were not available for all: 17 isolates
(out of 138 tested; 12.3%) gave a negative PZase enzymatic activ-
ity, indicating that a WT PZase does not exclude phenotypic re-
sistance a priori.
DISCUSSION
PZA DST is crucial for successful management of patients with
susceptible and drug-resistant TB, especially with MDR TB. Fur-
thermore, future shorter regimens for both drug-resistant and
drug-susceptible TB will include PZA as a key drug for achieving
both sterilization and prevention of the development of drug re-
sistance to new drugs (17, 18). Thus, reliable PZAr data for clinical
isolates are crucial for guiding the clinical management of pa-
tients. Phenotypic tests, however, have a long turnaround time,
are expensive, and are considered poorly reliable. As a conse-
quence, the design of a molecular test for predicting PZAr is a
priority. The development of a rapid molecular PZA DST is ham-
pered by the diverse nature of resistance-associated mutations
mainly scattered over the full length of the pncA gene, and by the
fact that the impact of individual mutations has not been system-
atically investigated (4, 12). Therefore, we performed a large-scale
study linking pncA sequence diversity with phenotypic, structural
biology and population biology data to develop the first encyclo-
pedia of pncA sequence variations linked to either a PZAr or PZAs
phenotype. This is likely to pave the way for application of new
genome-based sequencing technologies for predicting PZAr, al-
lowing for personalized treatment algorithms.
Strikingly, nearly 85% of the genetic variants identified in the
pncA gene were associated with phenotypic resistance to PZA and
were classified as “high-confidence” PZA resistance mutations. All
in-frame and frameshift indel mutations within the coding region
were included in this group. We found that nearly 90% of ob-
served mutations are associated with protein structural destabili-
zation that causes loss of enzymatic activity. Equally importantly,
we described 27 mutations most likely not involved in PZA resis-
tance that should be “filtered out” in future molecular tests and
labeled as not “clinically relevant” (Fig. 4). Only five mutations
cannot be classified by our approach and remain without clear
association with a resistance or susceptible phenotype. These mu-
tations need further validation for association with PZAr and/or
with a specific genetic background by an allelic exchange proce-
dure as performed for other drugs (19).
Discrepancies between molecular and phenotypic DST are
confusing for clinicians managing patients; 180 isolates investi-
gated here showed discrepant results between phenotypic and ge-
notypic tests (WT pncA gene sequence and resistance by Bactec
MGIT 960 DST). It has been reported that the Bactec MGIT 960
mycobacterial detection system may overestimate resistance even
in the best laboratory settings (due to changes in the medium pH
and/or variability in the inoculum size). Alternatively, a different
mechanism of resistance, such as mutations in rpsA, could also be
hypothesized for a few cases, although these were not clearly con-
firmed in clinical isolates (data not shown) (20–23). In Fig. S1 in
the supplemental material, we modeled the impact of these “dis-
crepant cases” in different hypothetical diagnostic scenarios to
provide worst and best performances of pncA sequencing-based
assay as follows. If all 180 cases were truly susceptible, the diag-
nostic accuracy of a molecular test for PZA based on sequence
would be 98.77% (95% confidence interval [95% CI], 98.18 to
99.17%) (Fig. S1C) in the range of the rifampin and isoniazid test
results (11). If the 180 cases were truly PZAr strains (wrongly
predicted as PZAs by pncA gene sequence), the diagnostic accuracy
of pncA sequencing in detecting PZAr would be 89.54% (95% CI,
89.21 to 90.82%), in the range of isoniazid resistance (Fig. S1B)
(11).
Based on our findings, any future molecular test for PZA resis-
tance should be able not only to detect the absence of the wild-type
sequence but also to identify the specific SNPs. We found, indeed,
a relevant number (10%) of mutations previously not reported as
associated with drug resistance (DR) and the degree of variability
in terms of indel mutations. In addition, we found mutations not
associated with DR, including the previously reported lineage-
specific genetic variants (e.g., TCC65TCT in Delhi/CAS) (14). Ac-
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cordingly, only an assay with the capacity to provide in-depth
sequence information could comply with the minimal require-
ments for a new molecular PZAr test. Fully automated, low-cost
medium-density arrays and user-friendly whole-gene/whole-
genome sequencing-based approaches will become a reality in the
very near future and will be the most suitable assays to fulfill this
task. In particular, new next-generation sequencing (NGS)-based
diagnostics could represent innovative tools to reduce false PZAr
cases and to improve safe and fast detection of drug resistances by
molecular DST (24). Our work has generated the minimum sets of
mutations that should be included in any molecular test for PZA
and provide a start point for a pncA genetic variation encyclopedia
needed for the valid interpretation of data generated by massive
sequencing approaches.
An additional aspect that is highlighted by our study is the great
advantage in sharing large data sets generated by several groups.
The establishment of a common database combining data from
clinical isolates collected in a large number of settings was crucial
to improve our understanding the role of pncA gene mutations in
determining the PZA susceptibility phenotype of M. tuberculosis.
The high number of samples providing sufficient reiteration of
less frequent mutations together with the inclusion of different
parameters (phenotype, genotype, enzymatic activity, structure,
and free energy analyses) in a decision tree allowed us to define
specific operational categories of mutations relevant from a clin-
ical point of view. This enabled us to build a user-friendly diag-
nostic algorithm through the classification of specific SNPs in a
shared database collecting more-complex information. These
large shared databases of mutations involved in drug resistance
could contribute to a better understanding of molecular mecha-
nisms of resistance, improved molecular diagnostics, new diag-
nostic algorithms, and better public health control of drug-
sensitive and drug-resistant TB.
MATERIALS AND METHODS
Strain selection. Strains were made available by six TB National/Supra-
national Reference and partner laboratories within the TB-PANNET
Consortium to provide wide coverage for most of the lineages observed
for the M. tuberculosis complex. Strains were tested for PZA susceptibility
and included in the study regardless of testing for other antitubercular
drugs. PZA drug susceptibility testing (DST) was performed by using a
Bactec MGIT 960 mycobacterial detection system and MGIT 960 PZA kits
(BD, Franklin Lakes, NJ, USA) according to the manufacturer’s instruc-
tions. A total of 1,950 clinical isolates were incorporated in the database.
Whenever available, genotyping information (spoligotyping and/or my-
cobacterial interspersed repetitive-unitvariable-number tandem-repeat
[MIRU-VNTR] typing [25]) were collected. The MIRU-VNTRplus web
tool (26, 27) was used to define lineage information (similarity search
settings for identification: 0.17; distance measure for MIRU-VNTR: cate-
gorical, weighting 1; distance measure for spoligotyping: categorical,
weighting 1).
pncA gene sequencing. DNA was extracted as described elsewhere
(28). The pncA gene (Rv2043c, NCBI gene identifier [ID] 888260), includ-
ing the proximal promoter region, was amplified. On a subset of samples,
the distal promoter region (100 bp upstream of the start codon) was also
included in the amplified region according to the protocol described in
reference 29. Amplicons were sequenced with an automated DNA se-
quencer. The pncA gene sequence of isolates from Samara, Russian Fed-
eration, was determined from whole-genome sequencing data as previ-
ously described (15). Mutations in the pncA gene were identified by
comparison with the wild-type M. tuberculosis H37Rv pncA gene se-
quence.
PZase assay. PZase activity was evaluated as described by Singh et al.
(30). Briefly, a Middlebrook 7H9 (BD, Franklin Lakes, NJ, USA) 1.5%
agarose containing PZA (Sigma-Aldrich Corporation, Saint Louis, MO,
USA) at a final concentration of 400 g/ml was prepared. Melted PZA
agar was distributed in glass tubes by using an agarose base to obtain a
semitransparent medium allowing the detection of a faint pink band
against a white background. A heavy loopful of actively growing culture
was carefully inoculated on the surface of the PZA agar medium and
incubated at 37°C for 4 days. One milliliter of ferrous ammonium sulfate
(1%) was added to each tube after incubation and observed for 4 h for the
appearance of a pink band (positive) in the subsurface agar. PZA-resistant
isolates of M. bovis (negative by the PZase test) were used as negative
controls, and the PZA-susceptible strain M. tuberculosis H37Rv was used
as a positive control. All isolates showing discrepant results (namely, pncA
mutant and PZase positive or WT pncA and PZase negative) were retested
at 4 and 10 days (31).
PZase structure. For each amino acid substitution, we performed an
in silico analysis of the free energy variation associated with the specific
mutation taking into account an acidic environmental pH (6.0), very close
to the one required for PZA activity. The crystal structure of the PZase
enzyme determined to 2.2-Å resolution (PDB code 3PL1) (32) was used in
conjunction with the program FoldX (33). Mean free energy variation was
calculated for triplicates of predicted structures, and based on statistical
analysis, a free energy variation greater than 2 kJ/mol was considered to
destabilize the enzyme. Frameshifts and mutations affecting the promoter
region were not considered. Free energy variation was then integrated
with a visual structural analysis in order to identify substitutions tolerated
by the free energy term but detrimental for the specific activity of the
enzyme.
Statistical analysis. For understanding the significance of each muta-
tion, we predicted the DST by fitting a conditional inference tree model
considering results of sequencing, activity, and the combination of struc-
ture and energy analyses as predictors. In the model, we applied recursive
partitioning based on conditional permutation tests. Furthermore, at
each step, P values were adjusted for multiplicity by the procedure of
Benjamini and Yekutiely (34). The majority of recursive partitioning al-
gorithms introduced since 1963 (35), such as CHAID and CART, yield
trees with too many branches and can also fail to pursue branches which
can add significantly to the overall fit. This leads to potential drawbacks:
overfitting and a selection bias toward covariates with many possible splits
or missing values (36, 37).
This approach is able to address missing data, since it uses surrogate
splits to determine the daughter node where the observations with miss-
ing values in the primary split variable are sent (for further details, see
references 38 and 39). As output of the model, given an isolate’s profile, a
conditional probability of being PZA resistant is given. As a general rule,
adjusted P values of less than 0.05 were considered significant. In the
model, we applied recursive partitioning based on conditional permuta-
tion tests. In fact, when splitting, the use of the conditional distribution of
the statistics ensures an unbiased selection of the covariates. This statisti-
cal approach prevented overfitting and overgrown trees, and no further
pruning or cross-validation was needed.
Further details on the rationale used for the analysis is available in the
supplemental material.
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